TY  - GEN
AU  - Andric, Zoran
AU  - Gálffy, Gabriella
AU  - Cobo Dols, Manuel
AU  - Szima, Barna
AU  - Stojanovic, Goran
AU  - Petrovic, Marina
AU  - Felip, Enriqueta
AU  - Vicente Baz, David
AU  - Ponce Aix, Santiago
AU  - Juan-Vidal, Oscar
AU  - Szalai, Zsuzsanna
AU  - Losonczy, Gyorgy
AU  - Calles Blanco, Antonio
AU  - Bernabe, Reyes
AU  - García Ledo, Gema
AU  - Aguilar Hernández, Andrés
AU  - Duecker, Klaus
AU  - Zhou, Dongli
AU  - Schroeder, Andreas
AU  - Guezel, Guelseren
AU  - Ciardiello, Fortunato
PY  - 2023
DO  - 10.1016/j.jtocrr.2022.100461
UR  - https://hdl.handle.net/20.500.12105/23105
AB  - INTRODUCTION: We present the results of a phase 2a trial of first-line avelumab (anti-programmed death-ligand 1 antibody) plus cetuximab (anti-EGFR antibody) in patients with advanced squamous NSCLC. METHODS: Patients with recurrent or metastatic...
LA  - eng
PB  - Elsevier
TI  - Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.
TY  - research article
ER  -